文献速递冠心病外科

冠状动脉旁路移植术后患者报告结局的最小临床重要差异:ART试验

Minimal clinically important differences in patient-reported outcomes after coronary artery bypass surgery in the arterial revascularization trial.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

该研究基于动脉血运重建试验(ART)数据,以纽约心脏协会(NYHA)心功能分级和加拿大心血管学会(CCS)分级改善1级为锚定,计算冠状动脉旁路移植(CABG)患者术后5年生活质量的最小临床重要差异(MCID),并评估其与10年随访死亡率的关联。

要点

  • 以NYHA为锚定,5年时SF-36躯体成分MCID为17,SF-36心理成分MCID为14,EQ-5D MCID为0.12。
  • 以CCS为锚定,5年时SF-36躯体成分MCID为15,SF-36心理成分MCID为12,EQ-5D MCID为0.12。
  • 5年时SF-36躯体成分和EQ-5D的MCID与术后10年随访较低死亡风险相关。

核心结论

  • 研究确定了CABG患者的MCID,这些阈值可能直接用于随访监测和设计以生活质量为主要结局的新试验。

研究设计与样本

  • 基于动脉血运重建试验(ART)的分析,在基线、5年和10年记录EQ-5D和SF-36躯体成分(PC)与心理成分(MC)评分。
  • MCID以5年时NYHA心功能分级和CCS分级改善1级为锚定计算。
  • 采用Cox比例风险模型评估MCID与死亡率的关联。
  • SF-36 PC分析队列N=2671,SF-36 MC分析队列N=2815,EQ-5D分析队列N=2943。

主要发现

  • CABG术后所有生活质量评分较基线显著改善。
  • 以NYHA为锚定,5年时MCID:SF-36 PC为17(95%CI 17-20),SF-36 MC为14(95%CI 14-17),EQ-5D为0.12(95%CI 0.12-0.15)。
  • 以CCS为锚定,5年时MCID:SF-36 PC为15(95%CI 15-17),SF-36 MC为12(95%CI 13-15),EQ-5D为0.12(95%CI 0.11-0.14)。

关键数值与推荐

  • 以NYHA为锚定,5年时SF-36 PC的MCID为17(95%CI 17-20)。
  • 以NYHA为锚定,5年时SF-36 MC的MCID为14(95%CI 14-17)。
  • 以NYHA为锚定,5年时EQ-5D的MCID为0.12(95%CI 0.12-0.15)。
  • 以CCS为锚定,5年时SF-36 PC的MCID为15(95%CI 15-17)。
  • 以CCS为锚定,5年时SF-36 MC的MCID为12(95%CI 13-15);EQ-5D的MCID为0.12(95%CI 0.11-0.14)。

临床怎么用

  • 5年时SF-36 PC和EQ-5D的MCID与术后10年随访较低死亡风险相关。
  • 作者认为这些阈值可能直接用于随访监测和设计以生活质量为主要结局的新试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This article identifies minimal clinically important differences (MCIDs) in quality of life (QoL) measures among patients who had coronary artery bypass grafting (CABG) and were enrolled in the arterial revascularization trial (ART). METHODS AND RESULTS: The European Quality of Life-5 Dimensions (EQ-5D) and the Short Form Health Survey 36-Item (SF-36) physical component (PC) and mental component (MC) scores were recorded at baseline, 5 years and 10 years in ART. The MCIDs were calculated as changes in QoL scores anchored to 1-class improvement in the New York Heart Association functional class and Canadian Cardiovascular Society scale at 5 years. Cox proportional hazard models were used to evaluate associations between MCIDs and mortality. Patient cohorts were examined for the SF-36 PC (N = 2671), SF-36 MC (N = 2815) and EQ-5D (N = 2943) measures, respectively. All QoL scores significantly improved after CABG compared to baseline. When anchored to the New York Heart Association, the MCID at 5 years was 17 (95% confidence interval: 17-20) for SF-36 PC, 14 (14-17) for the SF-36 MC and 0.12 (0.12-0.15) for EQ-5D. Using the Canadian Cardiovascular Society scale as an anchor, the MCID at 5 years was 15 (15-17) for the SF-36 PC, 12 (13-15) for the SF-36 MC and 0.12 (0.11-0.14) for the EQ-5D. The MCIDs for SF-36 PC and EQ-5D at 5 years were associated with a lower risk of mortality at the 10-year follow-up point after surgery. CONCLUSIONS: MCIDs for CABG patients have been identified. These thresholds may have direct clinical applications in monitoring patients during follow-up and in designing new trials that include QoL as a primary study outcome. CLINICAL TRIAL REGISTRATION NUMBER: ISRCTN46552265.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Masterson Creber R, Dimagli A, Niño de Rivera S, et al. Minimal clinically important differences in patient-reported outcomes after coronary artery bypass surgery in the arterial revascularization trial. Eur J Cardiothorac Surg. 2024. PMID: 38845077. doi:10.1093/ejcts/ezae208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。